Clinical Trial

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 8, 2025 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG003 and the combination of MRG003 and HX008 in patients with recurrent or metastatic squamous cell carcinoma of head and neck.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2021-04-29.
Trial Details
NCT Number NCT04868162
Lead Sponsor Shanghai Miracogen Inc.
Conditions Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck
Enrollment 116 participants
Start Date 2021-04-23
Primary Completion 2026-06 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-07-08